Schizoaffective Disorder — Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)
Citation(s)
Erhart SM, Young AS, Marder SR, Mintz J Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatry. J Clin Psychiatry. 2005 Aug;66(8):968-73.
Glynn SM, Cohen AN, Niv N New challenges in family interventions for schizophrenia. Expert Rev Neurother. 2007 Jan;7(1):33-43. Review.
Niv N, Cohen AN, Mintz J, Ventura J, Young AS The validity of using patient self-report to assess psychotic symptoms in schizophrenia. Schizophr Res. 2007 Feb;90(1-3):245-50. Epub 2007 Jan 3.
Niv N, Cohen AN, Sullivan G, Young AS The MIRECC version of the Global Assessment of Functioning scale: reliability and validity. Psychiatr Serv. 2007 Apr;58(4):529-35.
Young AS, Mintz J, Cohen AN, Chinman MJ A network-based system to improve care for schizophrenia: the Medical Informatics Network Tool (MINT). J Am Med Inform Assoc. 2004 Sep-Oct;11(5):358-67. Epub 2004 Jun 7.
Young AS, Mintz J, Cohen AN Using information systems to improve care for persons with schizophrenia. Psychiatr Serv. 2004 Mar;55(3):253-5.
Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
